Lisata Therapeutics (FRA:8NE) Other Current Receivables: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8NE Lisata Therapeutics Inc FRA:8NE
32 GF Score
Price €0.87
! 3 Warning Signs
View Full Analysis

What is Lisata Therapeutics Other Current Receivables?

Lisata Therapeutics FRA:8NE +1.75% 32 Other Current Receivables is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:8NE with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Lisata Therapeutics's Other Current Receivables for the quarter that ended in Jun. 2026 was €0.00 Mil.

Lisata Therapeutics Other Current Receivables Related Terms

Lisata Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Lisata Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lisata Therapeutics Other Current Receivables Chart

Lisata Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lisata Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:8NE
32GF Score
Lisata Therapeutics Inc FRA:8NE
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lisata Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.00 Mil mean?
Lisata Therapeutics (FRA:8NE) has a Other Current Receivables of €0.00 Mil as of Jun. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Lisata Therapeutics and its competitors.
Is Lisata Therapeutics' Other Current Receivables too high?
Lisata Therapeutics' current Other Current Receivables is €0.00 Mil. Overall, Lisata Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Lisata Therapeutics' Other Current Receivables compare to CYCN and OSRH?
Lisata Therapeutics' Other Current Receivables of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Lisata Therapeutics and its competitors. Lisata Therapeutics's current Other Current Receivables is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lisata Therapeutics stock overvalued right now?
Lisata Therapeutics (FRA:8NE) has a current Other Current Receivables of €0.00 Mil. The current Other Current Receivables is €0.00 Mil. Lisata Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Lisata Therapeutics (FRA:8NE), the current Other Current Receivables is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lisata Therapeutics Business Description

Other Exchanges LSTA:USA0HS8:UK
Address 110 Allen Road, 2nd Floor, Basking Ridge, NJ, USA, 07920
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
32GF Score

Get the complete analysis for FRA:8NE

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.87
Price